Market closed
Avid Bioservices/$CDMO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Avid Bioservices
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.
Ticker
$CDMO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
-
Website
Avid Bioservices Metrics
BasicAdvanced
$782M
Market cap
-
P/E ratio
-$2.28
EPS
1.38
Beta
-
Dividend rate
Price and volume
Market cap
$782M
Beta
1.38
52-week high
$12.24
52-week low
$4.07
Average daily volume
2.7M
Financial strength
Current ratio
1.458
Quick ratio
1.012
Long term debt to equity
348.869
Total debt to equity
353.766
Interest coverage (TTM)
-3.18%
Management effectiveness
Return on assets (TTM)
-3.05%
Return on equity (TTM)
-115.84%
Valuation
Price to revenue (TTM)
5.442
Price to book
13.29
Price to tangible book (TTM)
13.29
Price to free cash flow (TTM)
-67.651
Growth
Revenue change (TTM)
-5.28%
Earnings per share change (TTM)
4,313.89%
3-year revenue growth (CAGR)
12.04%
3-year earnings per share growth (CAGR)
177.50%
What the Analysts think about Avid Bioservices
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Avid Bioservices stock.
Avid Bioservices Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Avid Bioservices Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Avid Bioservices News
AllArticlesVideos
Punch and Associates sends letter to Board of Directors of Avid Bioservices, Inc.
Business Wire·1 week ago
AVID BIOSERVICES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avid Bioservices, Inc. - CDMO
Business Wire·2 weeks ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Avid Bioservices, Inc. – CDMO
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Avid Bioservices stock?
Avid Bioservices (CDMO) has a market cap of $782M as of November 22, 2024.
What is the P/E ratio for Avid Bioservices stock?
The price to earnings (P/E) ratio for Avid Bioservices (CDMO) stock is 0 as of November 22, 2024.
Does Avid Bioservices stock pay dividends?
No, Avid Bioservices (CDMO) stock does not pay dividends to its shareholders as of November 22, 2024.
When is the next Avid Bioservices dividend payment date?
Avid Bioservices (CDMO) stock does not pay dividends to its shareholders.
What is the beta indicator for Avid Bioservices?
Avid Bioservices (CDMO) has a beta rating of 1.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.